{"id":4134,"date":"2025-03-31T18:11:58","date_gmt":"2025-03-31T18:11:58","guid":{"rendered":"https:\/\/kidneydiseaseclinic.net\/kdc\/lenalidomide-txt\/"},"modified":"2025-03-31T18:11:58","modified_gmt":"2025-03-31T18:11:58","slug":"lenalidomide-txt","status":"publish","type":"post","link":"https:\/\/kidneydiseaseclinic.net\/kdc\/lenalidomide-txt\/","title":{"rendered":"Lenalidomide.txt"},"content":{"rendered":"

Lenalidomide <\/h1>\n

CLINICAL USE <\/H3>
\nTreatment of multiple myeloma in combination with dexamethasone

DOSE IN NORMAL RENAL FUNCTION <\/H3>25 mg daily on days 1\u201321 of a 28 day cycle; reduce dose if patient has neutropenia or thrombocytopenia; see data sheet

PHARMACOKINETICS <\/H3>
  • Molecular weight &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp :259.3<\/li>\n
  • %Protein binding &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp :22.7\u201329.2<\/li>\n
  • %Excreted unchanged in urine &nbsp &nbsp : 65\u201385<\/li>\n

  • Volume of distribution (L\/kg) &nbsp &nbsp &nbsp :86 litres<\/li>\n

  • half-life \u2013 normal\/ESRD (hrs)&nbsp &nbsp &nbsp :3.5\/>9

    DOSE IN RENAL IMPAIRMENT <\/H3>

    GFR (mL\/MIN)<\/H4>30\u201350 10 mg daily, increasing to 15 mg after 2 cycles if patient is not responding<30 15 mg every 48 hours

    DOSE IN PATIENTS UNDERGOING RENAL REPLACEMENT THERAPIES <\/H3>
  • CAPD &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp:Probably dialysed. 15 mg 2\u20133 times a week<\/p>\n
  • HD &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp :Probably dialysed. 15 mg 3 times a week post dialysis
  • HDF\/high flux &nbsp :Probably dialysed. 15 mg 3 times a week post dialysis
  • CAV\/VVHD &nbsp &nbsp &nbsp:Probably dialysed. Dose as in GFR=30\u201350 mL\/min

    IMPORTANT DRUG INTERACTIONS <\/H3>Potentially hazardous interactions with other drugsCardiac glycosides: possibly increases concentration of digoxin

    ADMINISTRATION <\/H3>

    Reconstition<\/H4>\u2013

    Route <\/H4>Oral

    Rate of Administration <\/H4>\u2013

    Comments<\/H4>\u2013

    OTHER INFORMATION <\/H4>May cause acute renal failure \u2013 monitor renal function during treatment. Patients with renal impairment are more likely to develop side effects
    \n","protected":false},"excerpt":{"rendered":"

    Lenalidomide CLINICAL USE Treatment of multiple myeloma in combination with<\/p>\n","protected":false},"author":1,"featured_media":0,"comment_status":"","ping_status":"","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[1],"tags":[7],"class_list":["post-4134","post","type-post","status-publish","format-standard","hentry","category-blog","tag-post-by-auto-php"],"_links":{"self":[{"href":"https:\/\/kidneydiseaseclinic.net\/kdc\/wp-json\/wp\/v2\/posts\/4134","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/kidneydiseaseclinic.net\/kdc\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/kidneydiseaseclinic.net\/kdc\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/kidneydiseaseclinic.net\/kdc\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/kidneydiseaseclinic.net\/kdc\/wp-json\/wp\/v2\/comments?post=4134"}],"version-history":[{"count":0,"href":"https:\/\/kidneydiseaseclinic.net\/kdc\/wp-json\/wp\/v2\/posts\/4134\/revisions"}],"wp:attachment":[{"href":"https:\/\/kidneydiseaseclinic.net\/kdc\/wp-json\/wp\/v2\/media?parent=4134"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/kidneydiseaseclinic.net\/kdc\/wp-json\/wp\/v2\/categories?post=4134"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/kidneydiseaseclinic.net\/kdc\/wp-json\/wp\/v2\/tags?post=4134"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}